Reuters logo
Eagle Pharmaceuticals sues FDA for denying exclusivity to new cancer drug
April 29, 2016 / 11:01 AM / 2 years ago

Eagle Pharmaceuticals sues FDA for denying exclusivity to new cancer drug

Eagle Pharmaceuticals Inc has sued the Food and Drug Administration for its refusal to grant its new cancer drug Bendeka seven years of marketing exclusivity as a so-called orphan drug for rare diseases.

In a complaint filed Wednesday in the U.S. District Court for the District of Columbia, Eagle said the FDA was flouting federal law and an earlier federal court order by refusing to grant exclusivity to Bendeka.

To read the full story on Westlaw Practitioner Insights, click here: bit.ly/1VEtGkR

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below